Search
Simcere LifeSciences' Novel Polθ Inhibitor SIM0508 Receives Clinical Approval for Combination Therapy with Olaparib
2025-08-20 /
Read about 0 minute
Author：小编
SIM0508, a small molecule inhibitor of DNA polymerase θ independently developed by Simcere Lifesciences, a subsidiary of Simcere Pharmaceutical Group, has secured clinical approval from the National Medical Products Administration for combination use with olaparib in the treatment of advanced solid tumors. As the first Polθ inhibitor to enter clinical research in China, SIM0508 marks a significant breakthrough in the anti-tumor "synthetic lethal" mechanism. Early clinical studies have demonstrated its excellent safety profile and tolerability, positioning it as a promising innovative therapy for the treatment of various solid tumors with homologous recombination defects.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
